乳腺癌患者术前乳腺MRI检出的BI-RADS 3类病变的管理
回顾性分析5110例乳腺癌患者术前MRI检出的626个BI-RADS 3类病变,恶性率为0.8%(5/626),中位检出至诊断间隔50个月,所有检出癌均为0期或IA期;作者认为年度随访可能足够。
要点
- 术前MRI检出的BI-RADS 3类病变恶性率0.8%(5/626),中位诊断间隔50个月。
- 所有由BI-RADS 3类病变诊断的癌症均发生在24个月随访之后。
- 检出癌均为0期或IA期,作者认为年度随访可能足够。
核心结论
- 术前MRI检出的BI-RADS 3类病变恶性率为0.8%(5/626),检出至诊断中位间隔50个月(范围29-66个月),所有检出癌均为0期或IA期,作者认为年度随访可能足够。
研究设计与样本
- 回顾性研究,从乳腺MRI数据库连续纳入5110例接受术前MRI和手术的乳腺癌患者,分析BI-RADS 3类评估的病变;以组织病理学结果或至少2年随访时的影像为参考标准。
关键影像表现/征象
- 626个BI-RADS 3类病变中,单发灶26.5%(166个)、多灶47.1%(295个)、肿块21.7%(136个)、非肿块强化4.6%(29个)。
- 总体恶性率0.8%(5/626),检出至诊断中位间隔50个月(范围29-66个月)。
- 按形态特征恶性率:单发灶1.8%(3/166),肿块0.7%(1/136),非肿块强化3.4%(1/29)。
- 所有检出的癌症均为0期或IA期。
诊断标准与关键数值
- BI-RADS 3类病变总体恶性率0.8%(5/626)。
- 单发灶恶性率1.8%(3/166),肿块0.7%(1/136),非肿块强化3.4%(1/29)。
- 所有癌症诊断均发生在24个月随访之后。
临床应用与阅片要点
- 作者认为,鉴于恶性率0.8%(5/626)、检出至诊断间隔长且检出癌均为早期,术前MRI检出的BI-RADS 3类病变年度随访可能足够。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To retrospectively evaluate characteristics of and determine appropriate follow-up recommendations for BI-RADS category 3 lesions detected in preoperative MRI of breast cancer patients.
METHODS: BI-RADS category 3 assessments were identified from the breast MRI database for 5,110 consecutive breast cancer patients who had undergone preoperative MRI and surgery. Patient and lesion characteristics, malignancy rate, and interval between lesion detection and cancer diagnosis were analysed. Histopathological results or imaging at or after 2-year follow-up were used as reference standards.
RESULTS: Of the 626 lesions, morphological features included a single focus in 26.5% (n = 166), multiple foci in 47.1% (n = 295), mass in 21.7% (n = 136) and non-mass enhancement in 4.6% (n = 29). Cancer was found in 0.8% (5/626) at a median interval of 50 months (range, 29-66 months). Malignancy rate according to morphological feature was: 1.8% (3/166) in a single focus, 0.7% (1/136) in mass and 3.4% (1/29) in non-mass enhancement. All detected cancers were stage 0 or IA.
CONCLUSIONS: Annual follow-up might be adequate for BI-RADS category 3 lesions detected at preoperative MRI because of the 0.8% (5/626) malignancy rate, long interval between lesion detection and cancer diagnosis, and early stage of diagnosed cancers.
KEY POINTS: • BI-RADS category 3 lesions on preoperative MRI had 0.8% malignancy rate. • All cancer diagnoses from BI-RADS 3 occurred after 24-month follow-up. • Annual follow-up might be adequate for BI-RADS 3 detected on preoperative MRI.
引用
- Gweon HM, Cho N, Kim SY, et al. Management for BI-RADS category 3 lesions detected in preoperative breast MR imaging of breast cancer patients. Eur Radiol. 2017. PMID: 28083693. doi:10.1007/s00330-016-4721-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。